Johnson & Johnson has announced that it will present 21 abstracts showcasing new clinical and real-world data at the 2025 Psych Congress Annual Meeting in San Diego, California, from September 17 to 21. The presentations will feature research from the company's neuropsychiatry portfolio, focusing on major depressive disorder, treatment-resistant depression, and schizophrenia. Notably, new Phase 3 data will be highlighted, demonstrating the safety and efficacy of seltorexant as an adjunctive treatment compared to quetiapine XR in major depressive disorder with insomnia symptoms. The data will include results from a head-to-head study evaluating seltorexant in combination with an oral antidepressant.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: CG72464) on September 15, 2025, and is solely responsible for the information contained therein.